Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

FDA Places Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept/Pembrolizumab in Advanced Cancers

March 8th 2022

The FDA has placed a partial clinical hold on the phase 1 NEON-2 trial examining the combination of davoceticept and pembrolizumab in patients with advanced solid tumors or lymphoma.

Adjuvant Pembrolizumab Improves Distant Metastasis–Free Survival in Resected Stage IIB and IIC Melanoma

March 7th 2022

Pembrolizumab significantly improved distant metastasis–free survival vs placebo when used as an adjuvant treatment in patients with resected stage IIB and IIC melanoma, according to additional data from the phase 3 KEYNOTE-716 trial.

Dr. Eroglu on the Utilization of ctDNA in Melanoma

March 1st 2022

Zeynep Eroglu, MD, discusses the utilization of circulating tumor DNA in patients with melanoma.

A Leader in the Revolution: Michael B. Atkins Is Giant of Cancer Care in Melanoma

February 24th 2022

“I don’t intend to rest on any laurels as thereis still much more to be done.”

Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1

February 17th 2022

Dr Milhem discusses the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial for patients with solid tumors, as well as the parallel studies ARTACUS and CERPASS, which are further exploring the agent.

Rapid Readouts: Results of Phase 3 DREAMseq Trial in Advanced Melanoma

February 9th 2022

Michael Atkins, MD, shares data presented at the 2021 American Society of Clinical Oncology Plenary Series regarding results from the phase 3 ECOG-ACRIN EA6134 trial, DREAMseq, evaluating the use of up-front dual immunotherapy in patients with BRAF V600–mutant advanced melanoma.

Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib Improves OS in BRAF V600–Mutated Advanced Melanoma

February 3rd 2022

Frontline administration of the checkpoint inhibitors ipilimumab plus nivolumab followed by the targeted agents dabrafenib plus trametinib improved overall survival in patients with BRAF V600–mutant melanoma vs the reverse sequence of combinations, according to data from the phase 3 DREAMseq trial presented during the ASCO Virtual Plenary Series.

FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma

January 26th 2022

The FDA has approved tebentafusp-tebn for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.

Cosibelimab Elicits Encouraging Responses in Metastatic Cutaneous Squamous Cell Carcinoma

January 25th 2022

The PD-L1 antibody cosibelimab, when given at a fixed dose of 800 mg every 2 weeks, elicited a promising objective response rate with acceptable safety and tolerability in patients with metastatic cutaneous squamous cell carcinoma, meeting the primary end point of a phase 1 registration-enabling trial.

New, Updated Data Demonstrate Promising Future in Advanced Melanoma

January 14th 2022

Jeffrey S. Weber, MD, PhD, overviews the successes made in the melanoma setting in the past decade and the challenges to overcome in the future.

Dr. Hamid on the Differences in Evaluation Criteria for TIL Therapy in Melanoma

January 12th 2022

Omid Hamid, MD, discusses the differences in evaluation criteria for tumor-infiltrating lymphocytes therapy in melanoma.

Dr. Hamid on the Efficacy of TILs Following Immunotherapy in Advanced Melanoma

January 12th 2022

Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.

Alpha DaRT Elicits Complete Responses in Malignant Skin and Soft Tissue Cancers

January 11th 2022

The diffusing alpha-emitter radiation therapy, Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial.

FDA Accepts IND for RM-1995 Photoimmunotherapy in Advanced Cutaneous or Head and Neck SCC

January 6th 2022

The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.

Neoadjuvant Immuno-oncology in the Treatment of Locally Advanced CSCC

January 3rd 2022

Our discussion closes with the presentation of phase 2 clinical trial data of neoadjuvant cemiplimab in locally regionally advanced cutaneous squamous cell carcinoma.

Clinical Case 3 Scenario

January 3rd 2022

Our final clinical case scenario is presented, and Kevin Emerick, MD, uses his experience to determine a proper course of action.

Using Other Therapies and the Future of Systemic Therapy for the Treatment of Advanced CSCC

January 3rd 2022

Drs In, Cohen, and Bakst discuss the use of other therapies for cutaneous squamous cell carcinoma, as well as what they believe is the future of systemic therapy for this disease.

KEYNOTE-629 Trial and Pembrolizumab

December 20th 2021

Dr In comments on data from the KEYNOTE-629 trial that focused on the use of pembrolizumab as a therapy option for patients with cutaneous squamous cell carcinoma.

Clinical Case 2 Continued

December 20th 2021

Drs Bakst and Cohen close out our second clinical case scenario by providing their thoughts on potential radiation therapy and using cemiplimab.

Dr. Weber Discusses Unmet Needs in Ocular and Mucosal Melanoma

December 15th 2021

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.